Curasight A/S (CPH:CURAS), a Denmark-based clinical stage radiopharmaceuticals company, announced on Thursday that the first patient has been successfully and safely dosed in the Phase 1 trial using uTREAT in brain cancer (high grade gliomas).

This marks the commencement of the first clinical trial under Curasight's therapeutic platform uTREAT, investigating it as a potential treatment option for glioblastoma.

The start of the Phase 1 study with uTREAT means that Curasight is now in the clinical phase with both parts of its theranostic platform aimed at improving treatment and diagnosis of certain cancers. The company's diagnostic platform uTRACE is currently in a Phase 2 trial for prostate cancer under the strategic partnership with Curium Inc.

The Phase 1 trial aims to investigate Curasight's uTREAT as a new type of targeted radiopharmaceutical therapy in glioblastoma patients. Participants in the trial are patients with newly diagnosed verified or suspected GBM.

Curasight's uPAR theranostic platform combines two key technologies, uTRACE and uTREAT, both targeting the uPAR receptor. uTRACE is designed to deliver sensitive imaging for diagnosis, while uTREAT provides a targeted radiopharmaceutical solution.